Last reviewed · How we verify
Enlon-Plus (Atropin)
Enlon-Plus (Atropin) is a small molecule anticholinergic medication originally developed by GD Searle LLC and currently owned by Alcon Labs Inc. It targets the muscarinic acetylcholine receptor M3 to treat perioperative mydriasis. Enlon-Plus is off-patent and has multiple generic manufacturers. It has a half-life of 4.1 hours and bioavailability of 50%. The medication has been FDA-approved since 1960.
At a glance
| Generic name | Atropin |
|---|---|
| Sponsor | Alcon Labs Inc |
| Drug class | Non-Standardized Insect Allergenic Extract [EPC] |
| Target | Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Perioperative Mydriasis
Common side effects
- Dizziness
- Drowsiness
- Sedation
- Headache
- Nausea
- Vomiting
- Abdominal discomfort
- Anorexia
- Restlessness
- Confusion
- Malaise/lethargy
- Depression
Serious adverse events
- Respiratory and/or CNS depression
- Toxic megacolon
- Paralytic ileus
- Megacolon
- Pancreatitis
- Anaphylaxis
- Angioneurotic edema
- Hallucination
- Hyperthermia
- Dehydration and electrolyte imbalance
Drug interactions
- cisapride
- pramlintide
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Premedication for Less Invasive Surfactant Administration Study (PRELISA) (PHASE4)
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
- Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PHASE4)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1,PHASE2)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enlon-Plus CI brief — competitive landscape report
- Enlon-Plus updates RSS · CI watch RSS
- Alcon Labs Inc portfolio CI